1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services; 2013 February 12. Available from: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf .
2. Bristol-Myers Squibb Company. REYATAZ® (atazanavir sulfate) Capsules: Prescribing Information. Bristol-Myers Squibb Company; 2013 August. Available from: http://packageinserts.bms.com/pi/pi_reyataz.pdf .
3. Bristol-Myers Squibb Company. BMS-232632: Atazanavir briefing document. Bristol-Myers Squibb Company; 2003 May. Available from: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3950B1_01_bristolmyerssquibb-atazanavir.pdf .
4. Busti AJ, Hall RG, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004;24(12):1732–47.
5. Welage LS, Carver PL, Revankar S, Pierson C, Kauffman CA. Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin Infect Dis. 1995;21(6):1431–8.